½üÄêÀ´£¬£¬£¬£¬£¬ÐÂÒ©Ñз¢Ô½À´Ô½¼èÄÑ£¬£¬£¬£¬£¬ÐÂÒ©ÎÊÊÀ³ÌÐò·Å»º¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬Ã¿Ò»¸öÐÂÒ©µÄÉÏÊж¼Òâζ×ÅÈËÀàÀë¹¥¿ËijÖÖ¼²²¡½üÁËÒ»²½£¬£¬£¬£¬£¬È缪ÏéµÂµÄ±û¸ÎÉñÒ©sofosbuvir£¬£¬£¬£¬£¬ÏÕЩÄܹ»¸ùÖαû¸Î£¬£¬£¬£¬£¬µ«´ÓÁíÍâÒ»¸ö½Ç¶ÈÀ´Ëµ£¬£¬£¬£¬£¬Ò©¼ÛµÄ½Ú½ÚÅÊÉýÒ²Èøü¶àÈËÖ»ÄÜÍûÒ©ÐË̾¡£¡£¡£ÐÂÒ©Ñз¢µÄ±¾Ç®ÓÖÊÇÔõÑùÖð²½ÅÊÉýµÖ´ï½ñÌìµÄ"Ìì¼Û"£¿£¿£¿ÐÂÒ©µÄÎÊÊÀΪºÎÔÆÔÆ¼èÄÑ£¿£¿£¿
Ö¸ÊýÔöÌíµÄÐÂÒ©±¾Ç®
±í1£ºÊý¾ÝÀ´×ÔCOVENCE CHINATRIALS¾Á¾Û»áPPT
ÔÚͼ1ÖУ¬£¬£¬£¬£¬ÎÒÃÇ¿ÉÒÔÇåÎúµØ¿´µ½ÐÂÒ©Ñз¢µÄÀú³ÌÖУ¬£¬£¬£¬£¬ÎÞÂÛÊÇÁÙ´²Ç°£¨Pre-Human£©ÕÕ¾ÉÁÙ´²£¨Clinical£©½×¶Î£¬£¬£¬£¬£¬×Ô1970ÄêÒÔÀ´Óöȶ¼ÔÚÒ»Ö±½Ú½ÚÅÊÉý£¬£¬£¬£¬£¬ÓÈÆäÊÇ1990-2000sÔçÆÚºÍ2000s-2010ÔçÆÚʱ´ú£¬£¬£¬£¬£¬ÁÙ´²Ç°ÓöÈÔöÌí151.8%£¬£¬£¬£¬£¬ÁÙ´²½×¶ÎÓöÈÔöÌí140.1.0%£¬£¬£¬£¬£¬ËùÓÐÓöÈÔöÌí145.0%¡£¡£¡£
Ðí¶àÐÂÒ©ÕÛêªÓÚIIIÆÚ½×¶Î£¬£¬£¬£¬£¬Ðí¶àÈ˶Դ˻ᱬ·¢Ò»¸öÎó½â£ºIIIÆÚ½×¶ÎÑз¢ÓöÈÒ»¶¨ÊÇÕ¼Õû¸öÁÙ´²ÊÔÑéÖбÈÖØ×î´óµÄ¡£¡£¡£µ«´Ó±í1ÖУ¬£¬£¬£¬£¬ÎÒÃÇ¿ÉÒÔ¿´µ½ÔÚ¢ñÆÚ¡¢¢òÆÚ¡¢IIIÆÚ½×¶ÎµÄÆÆ·Ñ²¢Ã»ÓÐÏÔ×ŵÄÇø±ð£¬£¬£¬£¬£¬Õâ¾ÍÒâζ×Å£¬£¬£¬£¬£¬×ÝÈ»ÐÂÒ©ÔÚIIIÆÚ½×¶ÎÑз¢Ê§°Ü£¬£¬£¬£¬£¬Ñз¢ÕßÒ²½«ÎªÇ°ÆÚµÄÖØ´óͶÈëÔâÊÜËðʧ¡£¡£¡£
±í2£ºÊý¾ÝÀ´×ÔCOVENCE CHINATRIALS¾Á¾Û»áPPT
ËäÈ»ÐÂÒ©Ñз¢ÏñÊÇһ̨Éî²»¼ûµ×µÄÎÞµ×¶´£¬£¬£¬£¬£¬Î£º¦ÐÔ¼«´ó£¬£¬£¬£¬£¬µ«ÐÂÒ©µÄ¿ª·¢ÀÖ³ÉÒâζ×ÅÖØ´óµÄÊг¡ºÍÀûÈ󣬣¬£¬£¬£¬Ðí¶àÊÀ½ç´óÒ©ÆóºÍͶ×ÊÈËÃÇÔ´Ô´Ò»Ö±µØÍ¶Ç®£¬£¬£¬£¬£¬ÒÔÍÆ½ø¸ü¶àµÄÐÂÒ©ÉÏÊУ¬£¬£¬£¬£¬×ÝȻÿһ¸öÐÂÒ©µÄÑз¢±¾Ç®Ô½À´Ô½¸ß¡£¡£¡£
±í3£ºResearch Spending Per New Drug£¨1997-2011£©
±í3£ºÊý¾ÝÀ´×ÔCOVENCE CHINATRIALS¾Á¾Û»áPPT
¿ØÖÆÐÂÒ©µÄ±¾Ç®ÒªËØ
¿ÆÎÄ˹ȫÇòÒ©ÎïÁÙ´²¿ª·¢ÈÏÕæÈËEric Lang¸±×ܲÃÒÔΪÐÂÒ©Ñз¢±¾Ç®µÄ×é³ÉÓУº
ÁÙ´²±¾Ç®£¨Clinical Procedures£©£¬£¬£¬£¬£¬
Ö°Ô±¹ÜÀí£¨Administrative Staff£©£¬£¬£¬£¬£¬
ÏÖ³¡¼àÊÓ±¾Ç®£¨Site Monitoring Costs£©¡£¡£¡£
Eric LangÒÔΪ£¬£¬£¬£¬£¬ÁÙ´²ÊÔÑ鯯·ÑÖнöÓÐ20%Ö±½ÓÓëÁÙ´²Êý¾ÝÏà¹Ø£¬£¬£¬£¬£¬ºÃ±È£¬£¬£¬£¬£¬ÁÙ´²ÊÔÑéÖб¬·¢µÄ´ó×ÚÑùÆ·ÐèÒª´æ´¢£¬£¬£¬£¬£¬¶øÕâЩ´æ´¢µÄÑùÆ·ÖÐÓÐÏ൱һ²¿·ÖÊDz»»á±»Ê¹ÓòâµÃÊý¾ÝµÄ£»£»£»£»£»Ò»Ð©ÌØÊâ´æÁôµÄÑùÆ·»á±»ÓÃÀ´ÖØÐ²ⶨ£¬£¬£¬£¬£¬ÒÔ×èֹʵÑéÖÐһЩ²»Ã÷È·µÄЧ¹û£¨ºÃ±ÈÊÔÑéµÎ¶¨Ð§¹û£©£»£»£»£»£»Ò»Ð©ÍøÂçµÄÊý¾Ý²¿·ÖÊÇΪÁËÈ¡ÔÃÄÉ˰È˺ÍͶ×ÊÕߣ¨È¨ºâ²¡È˵ÄÉúÑÄÖÊÁ¿£©¡¤¡¤¡¤ÊÔÑéÖÐ×îÖÕ±»ÆúÓõÄÊý¾Ý±ÈÀýÔÚ15%-30%¹æÄ£Ö®¼ä£¬£¬£¬£¬£¬ÕÛºÏÔ¼ÓÐÁ½ÍòÍòÖÁÁ½Ç§Îå°ÙÍòÃÀ½ð£¬£¬£¬£¬£¬¶øÕâЩÕýÊÇ¿ÉÒÔÖØÐ¿¼Á¿£¬£¬£¬£¬£¬Ñ¹Ëõ±¾Ç®µÄµØ·½¡£¡£¡£
Êý¾ÝÏÔʾ£¬£¬£¬£¬£¬Ö°Ô±¹ÜÀíÔÚÕû¸öÐÂÒ©Ñз¢Àú³ÌÖÐÕ¼µ½ÁË11%-20%µÄ±ÈÀý£¬£¬£¬£¬£¬ÏÖ³¡¼àÊÓ±¾Ç®ÔòÕ¼µ½9%-14%¡£¡£¡£Eric LangÌåÏÖ£¬£¬£¬£¬£¬ÏÖ³¡¼àÊÓ±¾Ç®¿ÉÒÔͨ¹ýÔ½·¢ÆÕ±éµØÊ¹ÓÃÒÆ¶¯¿Æ¼¼½øÒ»²½½µµÍ£¬£¬£¬£¬£¬¼¯Öд¦Öóͷ£ÆÊÎöÊý¾Ý¿ÉÒÔÓÃÀ´ÆÀ¹À¼àÊÓЧ¹û£¬£¬£¬£¬£¬µç×ÓÊý¾Ý²¶»ñ׼ȷÐÔÒÔ¼°Î£º¦¿ØÖÆ¡£¡£¡£
ÐÂÒ©µÄÎÊÊÀÔµºÎ·Å»º£¿£¿£¿
ÖÚËùÖÜÖª£¬£¬£¬£¬£¬ÐÂÒ©ÎÊÊÀ³ÌÐò·Å»ºµÄÒ»´óÒòËØ¾ÍÔÚÓÚÏÖ´úÒ½ÁÆË®Æ½²»¿É¹»ÍêÈ«ÏàʶÈËÌåÐÄÀí»úÖÆ£¬£¬£¬£¬£¬¸ü¶àʱ¼ä£¬£¬£¬£¬£¬ÐÂÒ©µÄÑз¢²»ÊÇ×Ô¶¯Éè¼ÆÒ©Îï·Ö×Ó£¬£¬£¬£¬£¬¶øÊÇÔÚããµÄÉúÎﻯѧ·Ö×ӵĺ£ÑóÖÐÕ÷²ÉÓÐDZÁ¦µÄÐÂÒ©£¬£¬£¬£¬£¬ÔÙ½øÒ»²½Ñо¿¿ª·¢¡£¡£¡£
ͬʱ£¬£¬£¬£¬£¬Ëæ×Åʱ´úµÄһֱǰ½ø£¬£¬£¬£¬£¬Ò©Æ·Çå¾²ÐÔÊܵ½Ô½À´Ô½¶àµÄÖØÊÓ£¬£¬£¬£¬£¬î¿Ïµ²¿·ÖÒ²³ǫ̈ÁËÔ½À´Ô½¶àµÄÕþ²ß¹æÔò£¬£¬£¬£¬£¬ÒªÇóÆóÒµÕÐļ¸ü¶àµÄÁÙ´²²¡Àý¡¢×ö¸ü¶àµÄÇå¾²ÐÔÊÔÑé¡¢Ìá½»¸üÏêϸµÄÊÔÑ鱨¸æ¡¤¡¤¡¤ÒÔ2000Äê-2008ÄêÊý¾ÝΪÀý£¬£¬£¬£¬£¬Ò©ÆóËù×öµÄÊÔÑéÉè¼Æ¡¢ÏîÄ¿µÄÖØ´óÐÔÒ²ÔÚÏÔ×ÅÉÏÉý¡£¡£¡£
±í4£ºÊý¾ÝÀ´×ÔCOVENCE CHINATRIALS¾Á¾Û»áPPT
ÓëÖ®Ïà¶ÔµÄÊÇ£¬£¬£¬£¬£¬ÃÀ¹úFDAƽ¾ùÉóÅúÐÂÒ©µÄʱ¼äÔÚÕû¸öÐÂÒ©Ñз¢ÉÏÊеıÈÖØÈ´ÔÚÖðÄêϽµ¡£¡£¡£
ͼ5£ºÊý¾ÝÀ´×ÔCOVENCE CHINATRIALS¾Á¾Û»áPPT
½áÓ
ÎÒ¹úÕþ¸®"Ê®ÈýÎåÍýÏë"¶¦Á¦´ó¾ÙÃãÀø±¾ÍÁÔÑÐÒ©¡¢Á¢ÒìÒ©µÄÑз¢£¬£¬£¬£¬£¬¹¤ÐŲ¿ÏûºÄ¹¤ÒµÆ·Ë¾¸±Ë¾³¤Î⺣¶«³Æ"Ò½Ò©¹¤ÒµÁ¢ÒìÉý¼¶ÒѳÉΪ¹ú¼ÒÕ½ÂÔ£¬£¬£¬£¬£¬Á¢Òì³ÉΪҽҩ¹¤Òµ'Ê®ÈýÎå'ÍýÏëµÄÒªº¦´Ê£¬£¬£¬£¬£¬Á¢ÒìÊÇÒ½Ò©¹¤ÒµÓÉ´óµ½Ç¿×ª±äµÄÒªº¦¡£¡£¡£"¿Æ¼¼²¿Éú³¤Õ½ÂÔÑо¿ÔºÔº³¤Íõºê¹ãÒ²ÌåÏÖ£¬£¬£¬£¬£¬"'Ê®ÈýÎå'ʱ´ú£¬£¬£¬£¬£¬Ò©Æ·ÖØ´óרÏԽ·¢¾Û½¹½¹µãÆ¿¾±¼¼Êõ£¬£¬£¬£¬£¬½â¾öÄÇЩ'¿¨²±×Ó'µÄÎÊÌâ¡£¡£¡£"
̫ͨ¹ýÎöÈ«ÇòÖÆÒ©¹¤ÒµÉú³¤Ç÷ÊÆ£¬£¬£¬£¬£¬»ò¿ÉΪÃÀ¸ß÷ÐÂÒ©Ñз¢Á¢Òì´øÀ´Ð©ÐíÖµµÃ½è¼øµÄÐÂ˼Ð÷¡£¡£¡£